Using Therapeutic Drug Monitoring To Treat Kpc-Producing Klebsiella Pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam

Mohamad Yasmin,Jennifer Hanrahan,Steven Marshall,Thomas P Lodise,Liang Chen,Federico Perez,Barry Kreiswirth,Robert A Bonomo
DOI: https://doi.org/10.1093/ofid/ofaa349
2020-01-01
Open Forum Infectious Diseases
Abstract:This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.
What problem does this paper attempt to address?